1111P Suboptimal real-world (RW) outcomes for BRAF+ metastatic melanoma (MM) patients in 2L therapy (The NOBLE study series)

Abstract

Targeted Therapy (TT) and immuno-oncology (IO) based therapy have each demonstrated significant clinical benefits when used in 1L for BRAF+ MM patients. However, there is very limited data available on characteristics and outcomes once MM patients progress on 1L treatment. To address this data gap, this study examined real-world disease severity, progression free survival (PFS) and overall survival (OS) outcomes in BRAF+ MM patients receiving 2L therapy and compared them to outcomes observed in 1L.